Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients

British Journal of Clinical Pharmacology

Volumn 63, Issue 5, 2007, Pages 541-547

  Naesens, Maarten ^a   Verbeke, Kristin ^b   Vanrenterghem, Yves ^a   Kuypers, Dirk ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Absorption; Gastric emptying; Mycophenolic acid pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CARBON 13; CARBON 14; GLYCINE; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTANOIC ACID; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CONFIDENCE INTERVAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RECIPIENT; STATISTICAL SIGNIFICANCE; STOMACH EMPTYING;

ADULT; AGED; BREATH TESTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; GASTRIC EMPTYING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE PERIOD;

EID: 34247324840     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02813.x     Document Type: Article

References (27)

1. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996 36 : 315 24.
2. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000 47 : 85 118.
3. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003 3 : 534 42.
4. Kuypers DRJ, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003 43 : 866 80.
5. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998 38 : 268 75.
6. van Hest R, Mathot R, Pescovitz MD, Gordon R, Mamelok R, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006 17 : 871 80.
7. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002 13 : 759 68.
8. Parker G, Bullingham R, Kamm B, Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996 36 : 332 44.
9. Hesselink DA, van Hest RM, Mathot RAA, Bonthuis F, Weimar W, de Bruin RWF, van Gelder T. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005 5 : 987 95.
10. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001 23 : 119 28.
11. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999 21 : 35 43.
12. Kuypers D, Verleden G, Naesens M, Vanrenterghem Y. Drug interaction between mycophenolate mofetil and rifampicin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther 2005 78 : 81 8.
13. Bullingham R, Shah J, Goldblum R, Shiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharm 1996 41 : 513 6.
14. Morii M, Ueno K, Ogawa A, Kato R, Yoshimura H, Wada K, Hashimoto H, Takada M, Tanaka K, Nakatani T. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000 68 : 613 6.
15. Kuypers D, Naesens M, Vermeire S, Vanrenterghem Y. The impact of UDP-glucuronosyl-transferase 1A9 (UGT1A9) gene promotor region single nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005 78 : 351 61.
16. van Hest R, Vulto A, Arnold G, Le Meur Y, van Gelder T. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004 26 : 620 5.
17. Akhlaghi F, Patel C, Zuniga X, Halilovic J, Preis I, Gohh R. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 2006 28 : 95 101.
18. van Gelder T, Le Meur Y, Shaw L, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 28 : 145 54.
19. van Hest R, Mathot R, Vulto A, Weimar W, van Gelder T. Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. Ther Drug Monit 2005 27 : 163 7.
20. Armbruster D, Tillman M, Hubbs L. Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 1994 40 : 1233 8.
21. Maes BD, Ghoos YF, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G. Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids. J Nucl Med 1994 35 : 824 31.
22. Kuypers DRJ, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. Drug Metab Dispos 2004 32 : 1421 5.
23. Guz G, Bali M, Poyraz NY, Bagdatoglu O, Yegin ZA, Dogan I, Atasever T, Sert S, Sindel S. Gastric emptying in patients on renal replacement therapy. Ren Fail 2004 26 : 619 24.
24. Bullingham R, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998 64 : 429 55.
25. van Gelder T, Hildebrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacity of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999 68 : 261 6.
26. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, Squifflet JP, Wallemacq P. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001 47 : 1241 8.
27. Greiff J, Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet 1994 27 : 447 61.